ESMO 2023

Preoperative checkpointinihition in ER+ disease

Highlights in eBC

5 year follow-up

Remarkable efficacies in patients with HER2+ mBC with…

DATO-DX - where is it going?

Clearing up non-clear cell RCC

The FGFR story in bladder cancer at ESMO23

Lu-PSMA leads forward

When the history of ADC is written: Redefining…

Early use of enzalutamide in advanced prostate cancer

Amivantamab as a new SoC for EGFR Exon 20…

Tarlatamab in SCLC

My highlights from ESMO 2023

ALINA - immediate change of practice!

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

What was the most exciting news at ESMO23?

Data updates for CDK4/6 inhibitors in EBC at ESMO23 -…

Anticipated updates and exciting new data for…

New and better biomarkers are needed!

My highlights of ESMO23 in early breast cancer

HR+ study with > 20 % PCR

Consolidation of data in early HR+ and triple-negative…

Carry-over effects in monarchE confirmed

ER-low corresponds diagnostically to ER-0 breast cancer

5 year follow-up

Negative EFS results from NeoTrip

Prognostic score in early HR+/HER2-BC: translational…

Neoadjuvant IO - is their new strategy in HR+ breast…

New data on neoadjuvant immunotherapy

Pembrolizumab solidifies as SOC in early-stage TNBC

Clinically relevant effect of pembro also in PCR

Detailed view of nodal-negative patients

Metabolomics reveal differential expression of OMEGA 3…

Use of immunotherapy in the perioperative setting of…

Highlights in eBC

Analysis of tumour microenvironment and…

MonarchE - trial update

Ribociclib effective in all subtypes

Our guidelines are correct

Immunoncology in eBC - triple negative and more?

MonarchE - mise à jour de l'essai

Punti salienti in eBC

Nouvelles données sur l'immunothérapie néoadjuvante

Studio NeoTrip: negativi i risultati

New ADC for metastatic breast cancer?

New targets, new linker, new ADCs - much more to learn…

ADCs in HER2+, HER2low and TNBC - what is the future of…

How to organize a molecular tumorboards in breast…

Improvement of therapy outcome by app-based patient…

Benefit for SG even after intensive pretreatment

My highlights of ESMO23 in metastatic breast cancer

Patient-centered molecular medicine - a new approach

Even more new generation ADCs in breast cancer?

Still on track for success in HER2-low MBC

Fulvestran better than anastrozole, but no survival…

ADC + Immunotherapy - the BEGONIA study paradigm

Can surgery be spared following primary systemic…

T-DXd also effective for brain metastases

OP seems to be dispensable for super responders

TULIP: Trastuzumab duocarmazine without OS benefit

Highlights in mBC

Abemaciclib remains consistent in 5-year follow-up

Dato-DXd - new player in advanced luminal disease

Remarkable efficacies in patients with HER2+ mBC with…

T-DXd in HER2+ patients with brain metastases

DATO-DX - where is it going?

TROP2 expression as a potential mechanism of resistance…

Our guidelines are correct

Robust data from the monarchE

OP-1250 (Palezestrant) confirms the role of SIRDs after…

T-DXd - new standard of care for brain mets?

Duvalumab + Dato-DXd effective

HS20089 - a novel ADC is coming for TNBC

HER2DX in the PHERgain trial

Improved oncological therapy with the smartphone

Dato-DXd - nowy gracz w zaawansowanym raku luminalnym

ADC + Immunothérapie: L'exemple de l'étude BEGONIA par…

La expresión de TROP2 como potencial mecanismo de…

Punti salienti in mBC

HER2DX en el estudio PHERgain

OP-1250 (Palezestrant) ulteriore conferma del ruolo dei…

Lo studio BEGONIA nelle paziento con tumore triplo…

HS20089 - un nuovo ADC che si affaccia sulla scenda del…

T-DXd - nowy standard postępowania w przerzutach do…

Should we use zoledronic acid in all ADT patients?

What is the future of immune therapy in prostate…

The optimal timing of RT after radical prostatectomy…

Longterm toxicity of adjuvant RT after prostatectomy

EMBARK - Quality of Life

TITAN: ultra-low PSA = best prognosis

Precision medicine at mCRCP

RADICALS RT: Trial and controversies

EMBARK expands ENZA indication to PCa

ENZA P:Trial and controversies

PSMA FORE: Trial and controversies

Brave New World in mCRPC

Big data and AI prediction tools

Lu-PSMA leads forward

CXCR2 inhibitor in PCa

Embark without fear

IO therapy in metastatic prostate cancer.

Osteoprotection at mHSPC

Salvage radiotherapy the new standard

When immunotherapy is probably not the best choice: The…

STAMPEDE. Bone prediction not for everyone - better…

Early use of enzalutamide in advanced prostate cancer

Combination of radioligand therapy with chemotherapy…

Negative data for pembrolizumab in mHSCPC & mCRPC

Immunotherapy in metastatic PCa

EMBARK och livskvalitet

Cuando la inmunoterapia probablemente no es la mejor…

Immunterapi vid prostatacancer

STAMPEDE data. Skelettstärkande och riskstratifiering.

CXCR2 hämmare och prostatacancer

Part 2: New standard of care in first line urothelial…

Part1: New standard of care in first line urothelial…

When the history of ADC is written: Redefining…

Chemo-IO establishes itself in the first-line treatment…

DAD, DAD-IO

New SoC in firstline bladder cancer

EV + Pembro as standard of care in first-line therapy…

The FGFR story in bladder cancer at ESMO23

Amazing new data in bladder cancer

Unique bladder delivery system of gemcitabine herolds…

Inhibidores de FGFR: Cual es el mejor escenario para…

L'histoire du FGFR dans le cancer de la vessie à…

Στιγμιότυπα για τον καρκίνο των νεφρών και της…

Where does the future therapy go in renal cell…

Is de-escalating therapy ready for prime-time?

Kidney cancer highlights at ESMO23

Clearing up non-clear cell RCC

Belzutifan in later lines of therapy

Intermittent therapy also possible with TKIs

New 3rd line therapy for RCC

Belzutifan - whats next kidney cancer?

Moving patients to the neoadjuvant setting in…

Substantial improvement in local regional NSCLC

ALINA - a new paradigm in operated NSCLC with…

Circulating DNA in AEGEAN trial

Perioperative IO: OS-benefi from KEYNOTE-671

Perioperativ immunotherapy for all resectable stage…

My highlights from ESMO 2023

Scene is set for inductive immunotherapy

ALINA - immediate change of practice!

Neoadjuvant chemo-immunotherapy new standards in early…

Adjuvant alectinib in patients with early-stage ALK+…

Gros progrès dans les traitments medicaeux des stades…

I miei punti salienti di ESMO 2023

ALINA - un nouveau paradigme dans cBNPC avec la fusion…

Les points forts de l'ESMO 2023

Activating EGFR-mutation - what's coming up?

Evolving landscape of ADCs

Rare oncogenic alterations: landmark results on exon 20…

Big improvements in early stage and a subset of…

Adagrasib + pembrolizumab in patients with KRASG12C…

PAPILLON - bringing together therapy for the 1st line

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

Treatment sequences for EGFR-mutated Patients

MARIPOSA II: Trial and controversies

Changing treatment landscape in EGFR-mutated NSCLC

Does immunotherapy still have a place in EGFR-positive…

Practice changing results on exon 20 insertion mNSCLC

My highlights from ESMO 2023

NRG fusions: a new drugable target?

Substantial improvement in rare alterations

Brain metastases – options to improve the systemic…

Amivantamab upfront? MARIPOSA trial

LIBRETO - a positive study, but was it necessary?

New standard of care for metastatic EGFR exon 20…

RET-TKI: Standard in 1st line RET fusion-positive NSCLC

Do ADCs have brain activity?

By unanimous decision and still the champion –…

TROPION-Lung01: positive development

MARIPOSA: Trial and controversies

Amivantamab at progression? MARIPOSA-2 trial

Nieuwe standaard voor gemetastaseerd EGFR exon20…

Heeft immunotherapie nog een plek in de behandeling van…

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

Les points forts de l'ESMO 2023

Gros progrès dans les traitments medicaeux des stades…

Quelles séquences thérapeutiques pour les patients EGFR…

Amivantamab at progression? MARIPOSA-2 trial

Amivantamab upfront? MARIPOSA trial

Veränderte Behandlungslandschaft bei EGFR-mutiertem…

I miei punti salienti di ESMO 2023

Tarlatamab in SCLC

A new option in relapsed SCLC

New data on sarkomas

PCO Therapeutics

First data on luveltamab in multiline treatment for…

Update on gynaecological cancers

Evolution of the revolution - the RUBY trial

New data on H&N Cancer